Trade 1000+ US stocks commission-free on the R StocksTrader platform<\/span><\/p>\n According to a report<\/a> by Grand View Research, the global biotechnology market was valued at 1.55 trillion USD in 2023. The compound annual growth rate (CAGR) is projected to reach 13.96% from 2024 to 2030.<\/p>\n\n\n\n Based on data<\/a> from Genetic Engineering & Biotechnology News, the market capitalisation of the top 25 biotechnology companies increased by nearly 78% from October 2019 to November 2023 inclusive, reaching 1.71 trillion USD.<\/p>\n\n\n\n The Food and Drug Administration (FDA) approved<\/a> 55 new therapeutics in 2023, marking the second-highest count in the past 30 years. In total, the regulator approved<\/a> 191 drugs throughout the last year, a 26% increase compared to the 2022 data. At the same time, 18 biotech companies went public<\/a> in 2023, the same as in 2022, while 2021 saw 108 initial public offerings.<\/p>\n\n\n\n The growth value was determined as the percentage difference between opening prices on 3 January and closing prices on 29 December 2023. The market capitalisation of each firm is indicated as of the material preparation date.<\/p>\n\n\n\n Founded in:<\/strong> 1999<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> Redwood City, California<\/p>\n\n\n\n Platform:<\/strong> NASDAQ<\/p>\n\n\n\n Market capitalisation:<\/strong> 1.43 billion USD<\/p>\n\n\n\n Soleno Therapeutics Inc. (NASDAQ: SLNO) specialises in developing and manufacturing drugs to treat rare genetic diseases. From January to December 2023, the company's stock value skyrocketed by 1825.84%, rising from 2.09 USD to 40.25 USD per unit.<\/p>\n\n\n\n On 26 September 2023, Soleno Therapeutics Inc. announced<\/a> positive results from clinical trials of its experimental drug DCCR for treating Prader-Willi syndrome.<\/p>\n\n\n\n According to the Q3 2023 report<\/a>, revenue for January to September 2023 inclusive was 0 USD. However, net loss increased by 49.03% compared to the same period in 2022, reaching 27.69 million USD or 2.65 USD per share.<\/p>\n\n\n\n Founded in:<\/strong> 2003<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> La Jolla, California<\/p>\n\n\n\n Platform:<\/strong> NASDAQ<\/p>\n\n\n\n Market capitalisation:<\/strong> 1.75 billion USD<\/p>\n\n\n\n Ambrx Biopharma Inc. (NASDAQ: AMAM) develops innovative drugs to treat oncology diseases. Its stock surged by 562.32% in 2023, from 2.15 USD to 14.24 USD per unit.<\/p>\n\n\n\n On 16 February 2023, the biotech company released<\/a> positive results from the phase 1 trial of ARX517, a drug for the treatment of prostate cancer. The medication demonstrated high effectiveness in reducing prostate-specific membrane antigen (PSMA) levels in patients with metastatic prostate cancer.<\/p>\n\n\n\n According to Ambrx Biopharma Inc.'s report<\/a> for Q3 2023, revenue from January to September inclusive plummeted 73.39% compared to the corresponding period in 2022 to 1.2 million USD, and net loss decreased by 16.31% to 56.11 million or 1.03 USD per share.<\/p>\n\n\n\n Founded in:<\/strong> 1987<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> Watertown, Massachusetts<\/p>\n\n\n\n Platform:<\/strong> NASDAQ<\/p>\n\n\n\n Market capitalisation:<\/strong> 0.79 billion USD<\/p>\n\n\n\n EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) is engaged in developing innovative methods for treating eye diseases. The company's shares surged by 550.99% in 2023, rising from 3.55 USD to 23.11 USD.<\/p>\n\n\n\n On 4 December 2023, EyePoint Pharmaceuticals Inc. announced<\/a> positive results from the phase 2 trial of EYP-1901, a drug developed to treat wet age-related macular degeneration.<\/p>\n\n\n\n Based on the Q3 2023 report<\/a> of EyePoint Pharmaceuticals Inc., revenue for January to September inclusive increased by 3.62% from the corresponding period in 2022, reaching 31.99 million USD, and net loss decreased by 3.58%, down to 56.70 million USD or 1.5 USD per share.<\/p>\n\n\n\n Founded in:<\/strong> 1980<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> Waltham, Massachusetts<\/p>\n\n\n\n Platform:<\/strong> NASDAQ<\/p>\n\n\n\n Market capitalisation:<\/strong> 8.25 billion USD<\/p>\n\n\n\n Immunogen Inc. (NASDAQ: IMGN) creates innovative drugs to treat oncology diseases. The corporation's stock surged by 496.58% over the past year, from 4.97 USD to 29.65 USD.<\/p>\n\n\n\n On 3 May 2023, Immunogen Inc. announced<\/a> positive results from the phase 3 trial of the ELAHERE drug for treating ovarian cancer. Based on these data, the company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for ELAHERE.<\/p>\n\n\n\n According to Immunogen Inc.'s report<\/a> for Q3 2023, revenue for nine months skyrocketed by 264.49% from the same period in 2022, reaching 246.45 million USD, while net loss was down 91.15% to 14.51 million USD or 0.05 USD per share.<\/p>\n\n\n\n Founded in:<\/strong> 2023<\/p>\n\n\n\n Registered in:<\/strong> the US<\/p>\n\n\n\n Headquarters:<\/strong> San Diego, California<\/p>\n\n\n\n Platform:<\/strong> NASDAQ<\/p>\n\n\n\n Market capitalisation:<\/strong> 1.43 billion USD<\/p>\n\n\n\n Founded<\/a> on 30 October 2023 following the completion of the business merger between Catalyst Biosciences Inc. and Beijing Continent Pharmaceuticals Co. Ltd., Gyre Therapeutics Inc. (NASDAQ: GYRE) develops drugs for treating liver fibrosis across a broad spectrum of chronic liver diseases. In 2023, the corporation's stock soared 389.33% from 5.25 to 25.69 USD per unit.<\/p>\n\n\n\n According to the Q3 2023 report<\/a> of Catalyst Biosciences Inc., revenue for January to September inclusive was 0 USD. Net loss amounted to 3.78 million USD or 0.10 USD per share, while a year ago, the company posted a net profit of 32.21 million USD or 1.02 USD per share.<\/p>\n\n\n\n Evaluating biotechnology stocks requires a comprehensive approach that considers their activities' financial and scientific aspects. Here are the key points to focus on:<\/p>\n\n\n\n Clinical trials constitute a vital component of the new product development process in the biotechnology market. However, they tend to be both expensive and labour-intensive. According to projections<\/a> from PDD experts, clinical trials are expected to become more accessible and efficient in 2024. This improvement is attributed to using artificial intelligence, enhanced computational capabilities, and the expansion of data volumes.<\/p>\n\n\n\n PDD specialists anticipate that regulatory authorities will place greater emphasis on the diversity of clinical trial participants. This shift in focus could create favourable conditions for enhancing the effectiveness, accessibility, and safety of new medications. The rationale is that treatments and methodologies that may not yield positive outcomes for one group of patients might align more closely with anticipated results when applied to another group.<\/p>\n\n\n\n Cell and gene therapies stand out as groundbreaking advancements in biotechnologies. They hold the potential to treat diseases previously deemed incurable successfully. According to data<\/a> from Markets and Markets, a substantial increase in clinical trials and approvals for advanced treatment methods is expected in 2024. The focus will be on utilising CAR-T, TCR-T, stem cells, and gene editing.<\/p>\n\n\n\n Enter the ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/free-stocks-mobile.png\")
\n <\/div>\n Start Now<\/a>\n <\/div>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/free-stocks-descktop.png\")
\n <\/div>\n <\/div>\n\n\n\n<\/span><\/a>The biotechnology sector in 2023: an overview<\/span><\/h2>\n\n\n\n
<\/span><\/a>Our methodology<\/span><\/h2>\n\n\n\n
\n
<\/span><\/a>Top-performing biotech stocks of 2023<\/span><\/h2>\n\n\n\n
<\/span><\/a>1. Soleno Therapeutics: +1826%<\/span><\/h3>\n\n\n
<\/span><\/a>2. Ambrx Biopharma: +562%<\/span><\/h3>\n\n\n
<\/span><\/a>3. EyePoint Pharmaceuticals: +551%<\/span><\/h3>\n\n\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/prime1-mobile.png\")
\n <\/div>\n Open a Prime Account<\/a>\n <\/div>\n ![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/prime1-desktop.png\")
\n <\/div>\n <\/div>\n\n\n\n<\/span><\/a>4. Immunogen: +497%<\/span><\/h3>\n\n\n
<\/span><\/a>5. Gyre Therapeutics: +389%<\/span><\/h3>\n\n\n
<\/span><\/a>Risks and challenges in biotech investing<\/span><\/h2>\n\n\n\n
\n
<\/span><\/a>Investor insights: how to evaluate biotech stocks<\/span><\/h2>\n\n\n\n
\n
<\/span><\/a>Future outlook: what’s next for biotech in 2024 and beyond?<\/span><\/h2>\n\n\n\n
<\/span><\/a>Accessibility and efficiency of clinical trials<\/strong><\/span><\/h3>\n\n\n\n
<\/span><\/a>Diversity of clinical trial participants<\/strong><\/span><\/h3>\n\n\n\n
<\/span><\/a>Progress in cell and gene therapies<\/strong><\/span><\/h3>\n\n\n\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rst-mobile.png\")
\n <\/div>\n Try Now<\/a>\n <\/div>\n
![\"partner-programme\"](\"https:\/\/www.robomarkets.com.cy\/blog\/wp-content\/uploads\/2023\/09\/rst-desktop.png\")
\n <\/div>\n <\/div>\n\n\n\n